Tag

Health Care Archives | Page 129 of 137 | Smartkarma

Apr 03
0

Health Care: Shanghai Junshi Bioscience Co. Ltd. and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Shanghai Junshi Bioscience (1877 HK): Uncertainties Prevailing Ahead of First U.S. Drug Approval

Shanghai Junshi Bioscience (1877 HK): Uncertainties Prevailing Ahead of First U.S. Drug Approval

By Tina Banerjee

  • Shanghai Junshi Bioscience Co. Ltd. (1877 HK)’s oncology drug candidate toripalimab marketing application is currently under priority review by the FDA, with a target action date of April 30, 2022.
  • However, FDA may reject toripalimab application, as it is predominantly based on China clinical trial data. Toripalimab may also face delay in FDA decision due to delayed regulatory inspection.
  • PD-1 drug market in the U.S. is intensely competitive, making the commercialization prospect of a new drug quite difficult. Toripalimab reported muted performance in China due to pricing headwind.

Before it’s here, it’s on Smartkarma

Learn More
Apr 01
0

Health Care: Burning Rock Biotech, Guanze Intelligent Medical Information Industry Holding, Mitra Keluarga Karyasehat Tbk, Ono Pharmaceutical and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Burning Rock Biotech (BNR US): Attractive Growth Story Outshined by Surging COVID Cases in China
  • Pre-IPO Guanze Intelligent Medical Information Industry – Advantages in Shandong Cannot Hide Worries
  • Mitra Keluarga (MIKA IJ) – Back On a Digitally Enhanced Expansion Tack
  • Japan’s Governance: Ono Pharmaceutical (4528) ESG Briefing

Burning Rock Biotech (BNR US): Attractive Growth Story Outshined by Surging COVID Cases in China

By Tina Banerjee

  • Burning Rock Biotech (BNR US) shares plunged 35% since I published bearish insight on the company in November. Weak Q3 results, slower recovery, and the U.S.-China conflict remained major overhangs.
  • However, the shares are now trading at two-week high, as the company received approval for its second NGS kit in China and reported slightly better-than-expected Q4 results.
  • Investors should continue to avoid Burning Rock shares for near-term and wait for COVID cases to subside in China and resolution of the U.S.-China conflict.

Pre-IPO Guanze Intelligent Medical Information Industry – Advantages in Shandong Cannot Hide Worries

By Xinyao (Criss) Wang

  • Guanze relies heavily on sale of medical imaging film products in Shandong Province, and occupies a leading market position in Shandong based on its accumulation in local networks and resources.
  • However, the market size in Shandong is limited, with growth ceiling.With the trend of new technology and unproven ability to expand nationwide,there’s a risk of being eliminated in long term.
  • In this context, Guanze could face a lot of challenges and uncertainties. Therefore, we are conservative about the Company’s outlook at the current stage.

Mitra Keluarga (MIKA IJ) – Back On a Digitally Enhanced Expansion Tack

By Angus Mackintosh

  • Mitra Keluarga Karyasehat Tbk (MIKA IJ) booked a strong set of FY2021 results driven by both COVID treatments and the start of a recovery in its core base case business.
  • The company is back on an expansion tack in 2022, with increased capex and new hospital openings plus an increasing focus on digital initiatives.
  • Mitra Keluarga Karyasehat Tbk (MIKA IJ) remains a core proxy for the growing penetration of healthcare in Indonesia and valuations are attractive versus history.

Japan’s Governance: Ono Pharmaceutical (4528) ESG Briefing

By Aki Matsumoto

  • The corporate governance efforts are making gradual progress, and I appreciate the company’s disclosure of issues, but I would like to see it become more proactive.
  • Policy shareholding is one of its biggest challenges. Establishing a path for reducing the shareholdings and disclosing and showing progress in doing so shows that it is addressing the issue.
  • Good progress has been made on the protection of environment. Regarding the expansion of human capital, the initiative has only just begun and is expected further efforts in the future.

Before it’s here, it’s on Smartkarma

Learn More
Mar 31
0

Health Care: Jiangsu Recbio Technology, Aurobindo Pharma, Sri Trang Gloves (Thailand) Public Company Limited and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • RecBio (江苏瑞科) IPO Trading: Fairly Valued for Vaccine Hype
  • Aurobindo-Veritaz Acquisition: No Justice
  • Sri Trang Gloves (Thailand) Public Company Limited (STGT TB): Short-Term Pain; Long-Term Gain

RecBio (江苏瑞科) IPO Trading: Fairly Valued for Vaccine Hype

By Ke Yan, CFA, FRM

  • Jiangsu RecBio raised HKD 672m (USD 86m) from its global offering and will list on the Hong Kong Stock Exchange on Thursday, March 31st.
  • In the previous note, we looked at the company’s core products, including its HPV portfolio and the COVID-19 vaccine. 
  • In this note, we provide an update for the IPO before trading debut.

Aurobindo-Veritaz Acquisition: No Justice

By Nitin Mangal

  • On Monday, Aurobindo Pharma (ARBP IN) had announced the acquisition of the branded generic business and certain assets of Veritaz Healthcare Limited for a cash consideration of INR 1.7 bn.
  • It should be known that Veritaz is a promoter group entity, which is why acquisition will fall within the scope of Related Party Transactions.
  • Being a promoter company and having had some red flags in the past such as negative net-worth, continuous loss making nature, etc. The cash consideration looks questionable.

Sri Trang Gloves (Thailand) Public Company Limited (STGT TB): Short-Term Pain; Long-Term Gain

By Tina Banerjee

  • Riding on COVID-driven demand boom, Sri Trang Gloves (Thailand) Public Company Limited (STGT TB) reported record high performance in 2021, which is not likely to continue in near-term.
  • However, post pandemic, gloves demand is expected to improve on the back of increased glove usage from emerging markets with low gloves consumption per capita and heightened hygiene awareness.
  • STGT shares have corrected 15% thus far in this year, providing a good buy on dip opportunity. Shares can be considered for the long-haul.

Before it’s here, it’s on Smartkarma

Learn More
Mar 30
0

Health Care: Apollo Hospitals Enterprise, CSPC Pharmaceutical Group and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • NIFTY Index Rebalance: Flows at the Close Today
  • CSPC Pharmaceutical Group (1093.HK) – Conservative About the Business Transformation Outlook

NIFTY Index Rebalance: Flows at the Close Today

By Brian Freitas

CSPC Pharmaceutical Group (1093.HK) – Conservative About the Business Transformation Outlook

By Xinyao (Criss) Wang

  • Due to the lack of differentiated and frontier enough target layout, the commercialization potential would be more easily questioned, with high uncertainty of having the next NBP level products.
  • CSPC has made easy money from a few large varieties/generic drugs for many years, but is destined to make the business transformation more difficult, because the “opportunity cost” is high.
  • CSPC’s products have lost their pricing power. Therefore, when its valuation is very low or the entire sector is moving upward, this stock could be traded due to positive momentum.

Before it’s here, it’s on Smartkarma

Learn More
Mar 29
0

Health Care: Hutchison China MediTech Ltd and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Hutchmed China Ltd (13.HK/HCM.US) – Big but Not Strong

Hutchmed China Ltd (13.HK/HCM.US) – Big but Not Strong

By Xinyao (Criss) Wang

  • For the three commercialized products (fruquintinib, surufatinib and savolitinib), they are facing challenges from different aspects. 
  • The lack of blockbuster products and promising targets indicates that Hutchmed’s current pipeline does not have core competitiveness, which means Hutchmed’s position in the industry is not in first echelon.
  • In fact, Li Ka-shing’s positioning and original intention for Hutchmed is not on innovative drugs. So, big but not strong has always been the pain point of the Company.

Before it’s here, it’s on Smartkarma

Learn More
Mar 28
0

Health Care: Prodia, Siloam International Hospitals, Akeso Biopharma Inc and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Prodia (PRDA IJ) – Diagnosed for Growth
  • Siloam International Hospitals (SILO IJ) – Core Strength in Display
  • Akeso Biopharma Inc (9926.HK) – Caution Is Advised Until Sufficient Financing Is Secured

Prodia (PRDA IJ) – Diagnosed for Growth

By Angus Mackintosh

  • Prodia (PRDA IJ) released an exceptionally strong set of FY2021 results, driven partly by COVID testing but coupled by a pick-up in its core testing business and especially esoteric testing.
  • It continues to see increasing tests per visit with revenue per visit increasing at the same time. Its digital strategy is working well further driving growth through an omnichannel approach.
  • Prodia (PRDA IJ) continues to look dramatically undervalued versus its Indian diagnostic peers given its quality and growth prospects and remains our top Indonesian healthcare pick.

Siloam International Hospitals (SILO IJ) – Core Strength in Display

By Angus Mackintosh

  • Siloam International Hospitals (SILO IJ) held an analyst briefing recently to highlight the strong recovery of its base-case business, with very little contribution from COVID-related treatments by year-end.
  • Revenues on a monthly basis have hit record highs in December and January, with increased efficiencies and improving profitability due to cost controls.
  • Siloam International Hospitals (SILO IJ) remains an interesting recovery play but it has emerged even stronger from the pandemic and valuations are attractive versus peers and history. 

Akeso Biopharma Inc (9926.HK) – Caution Is Advised Until Sufficient Financing Is Secured

By Xinyao (Criss) Wang

  • Akeso has a very high starting point, and was regarded as the leader of domestic second-tier biotech companies. However, in current unfavorable market sentiment, it’s necessary to re-examine the Company.
  • In Akeso’s pipeline, there are some valuable and differentiated candidates, especially in the field of bispecific antibodies. Its R&D capability is also well recognized.
  • However, due to the rich pipeline, related clinical trials will drain money fast. So, investors are advised to be cautious until Akeso has ensured sustainable and stable cash flow.

Before it’s here, it’s on Smartkarma

Learn More
Mar 27
0

Health Care: PolyNovo Ltd and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • PolyNovo (PNV AU): Positive Momentum in U.S. Is Overshadowed by Cost Pressure and Lofty Valuation

PolyNovo (PNV AU): Positive Momentum in U.S. Is Overshadowed by Cost Pressure and Lofty Valuation

By Tina Banerjee

  • PolyNovo Ltd (PNV AU) develops, manufactures, and markets artificial dermal templates. The company has only one marketed product and 88% of total revenue comes from the U.S.
  • Although U.S. business is on high trajectory, the company’s drive to expand sales team and pipeline progress are putting pressure on the profitability, which do not justify the superior valuation.
  • I would like to wait for PolyNovo to become profitable post its investment for growth, start offering multiple differentiated products, with sizable presence in OUS markets, to have higher conviction.

Before it’s here, it’s on Smartkarma

Learn More
Mar 26
0

Health Care: Caplin Point Laboratories and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Caplin Point Labs: Forensic Analysis

Caplin Point Labs: Forensic Analysis

By Nitin Mangal

  • Caplin Point Laboratories (CLPL IN)  develops, produces, markets, and exports generic pharmaceutical formulations and branded products, including liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules etc.
  • While Caplin has a healthy 5 year CAGR growth ~28% and strong margins, it however has slowed down recently. The return ratios, turnover and cash conversion have been heading southwards.
  • There have been some dubious accounting related to cash flows and asset quality, and few red-flags relating to few of the subsidiaries as well which should not be overlooked.

Before it’s here, it’s on Smartkarma

Learn More
Mar 25
0

Health Care: Beijing Tiantan Biological Products, CSPC Pharmaceutical Group and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Presentation for Impact of Russia/Ukraine War on Asian Markets-Tiantan Biological Products(600161CH)
  • CSPC Pharmaceutical (1093 HK): 2021 Results Review- Double-Digit Top-Line Growth, Driven By Oncology

Presentation for Impact of Russia/Ukraine War on Asian Markets-Tiantan Biological Products(600161CH)

By Xinyao (Criss) Wang

  • In the context of both the war and the pandemic, the blood products market would be a field of high-quality investment. 
  • Due to strict policy supervision, the number of plasma stations is the core competitiveness of enterprises in this industry, which basically determines the scale and outlook of blood products enterprises. 
  • With the background of state-owned enterprise and also having the most plasma stations among peers,Tiantan Biological Products (600161 CH) has an innate advantage over other competitors, with more certainty in long term.

CSPC Pharmaceutical (1093 HK): 2021 Results Review- Double-Digit Top-Line Growth, Driven By Oncology

By Tina Banerjee

  • CSPC Pharmaceutical Group (1093 HK) shares climbed nearly one-month highs after strong 2021 results and new drug approval. The company has recommended final dividend of HKD 0.10/share.  
  • 2021 revenue increased 12% y/y to RMB28 billion, mainly driven by the growth in the finished drug businesses. This has eased concern of CSPC’s revenue sensibility to pricing headwind.
  • The company is on track to launch more than 30 innovative and new-formulation drugs, and over 60 generic drugs in the next five years.

Before it’s here, it’s on Smartkarma

Learn More
Mar 24
0

Health Care: Abbvie Inc and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • AbbVie Inc (ABBV US): Great Value Stock to Buy in Choppy Market

AbbVie Inc (ABBV US): Great Value Stock to Buy in Choppy Market

By Tina Banerjee

  • Abbvie Inc (ABBV US) shares remained rangebound in 2021, mainly due to Humira patent expiration overhang. Humira is the flagship drug of the company, accounting for 37% of total revenue.
  • Increasing label expansion of its two other drugs, Skyrizi and Rinvoq are now increasingly opening up new growth avenues for AbbVie. Together these drugs contributed 8% to total revenue.
  • Attractive valuation and healthy dividend yield make AbbVie a top value investment idea amid this turbulent time.

Before it’s here, it’s on Smartkarma

Learn More